vTv Therapeutics completes enrollment in Phase 3 type 1 diabetes trial
Tweet Send to a Friend
vTv Therapeutics Inc. (Nasdaq: VTVT) announced the completion of enrollment in its Phase 3 CATT1 study evaluating cadisegliatin as an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




